NervGen Pharma Corp.(NGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NGEN NervGen Pharma Corp.

未开盘 05-27 16:00:00 EDT

2.07

-0.06

-2.82%

盘后2.07

+0.000.00%

19:57 EDT

最高2.15	最低2.05	成交量152.23万
今开2.14	昨收2.13	日振幅4.69%
总市值1.70亿	流通市值1.45亿	总股本8,219万
成交额317.44万	换手率2.17%	流通股本7,017万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":2.07,"timestamp":1779912000000,"preClose":2.13,"halted":0,"volume":1522298,"hourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:57 EDT","volume":37311,"amount":77262.4593,"timestamp":1779926222369,"change":0,"changeRate":0,"amplitude":0.014493},"delay":0,"changeRate":-0.028169014084507067,"floatShares":70170200,"shares":82193100,"eps":-0.401633,"marketStatus":"未开盘","change":-0.06,"latestTime":"05-27 16:00:00 EDT","open":2.14,"high":2.15,"low":2.05,"amount":3174357.8993583997,"amplitude":0.046948,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.401633,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779955200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.13,"preHourTrading":{"tag":"盘前","latestPrice":2.14,"preClose":2.13,"latestTime":"09:29 EDT","volume":22303,"amount":47791.1248845,"timestamp":1779888599999,"change":0.01,"changeRate":0.004695,"amplitude":0.063662},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:57 EDT","volume":37311,"amount":77262.4593,"timestamp":1779926222369,"change":0,"changeRate":0,"amplitude":0.014493},"volumeRatio":0.40055,"impliedVol":1.7622,"impliedVolPercentile":0.5747},"requestUrl":"/m/hq/s/NGEN","defaultTab":"news","newsList":[{"id":"1133039688","title":"NervGen Pharma Corp - Nvg-291在1B/2a期Connect Sci研究中显示出统计学显著的步态质量改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1133039688","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133039688?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:16","pubTimestamp":1779794209,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp. 宣布，其研究性药物Nvg-291在针对多发性硬化症患者的1B/2a期Connect Sci临床研究中，取得了具有统计学显著意义的步态质量改善。研究数据显示，与安慰剂组相比，接受Nvg-291治疗的患者在步态分析的关键指标上表现出显著提升。Nvg-291是一种旨在促进神经修复和功能恢复的新型疗法。公司表示，将继续推进相关临床开发计划，以进一步评估Nvg-291在更广泛神经系统适应症中的安全性与有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174712044","title":"NervGen Pharma Corp启动普通股、认股权证及预融资认股权证承销公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1174712044","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174712044?lang=zh_cn&edition=full","pubTime":"2026-05-22 04:04","pubTimestamp":1779393853,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp.宣布，公司已启动一项承销公开发行，将发行普通股、认股权证及预融资认股权证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102911496","title":"NervGen Pharma 公司——净收益将用于推进Nvg-291临床研究及一般公司用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1102911496","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102911496?lang=zh_cn&edition=full","pubTime":"2026-05-22 04:04","pubTimestamp":1779393852,"startTime":"0","endTime":"0","summary":"NervGen Pharma 公司宣布，此次融资所得净收益将主要用于推进其核心候选药物Nvg-291的临床研究，并支持公司的一般运营与战略发展。此举旨在加速该疗法的开发进程，为未来的商业化奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118353180","title":"NervGen药业任命基思·文多拉为首席财务官，强化领导团队实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1118353180","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118353180?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:35","pubTimestamp":1777289732,"startTime":"0","endTime":"0","summary":"NervGen药业公司宣布任命基思·文多拉担任首席财务官，这一关键人事变动将显著增强公司的领导团队架构。此次高层调整旨在优化企业财务战略布局，为后续业务拓展提供强有力的支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130972687","title":"NervGen Pharma Corp. 即将完成1B/2a期CONNECT-SCI亚急性四肢瘫患者入组并揭盲数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1130972687","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130972687?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:31","pubTimestamp":1775561476,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp. 宣布，其针对亚急性脊髓损伤导致四肢瘫患者的1B/2a期CONNECT-SCI临床试验即将完成患者入组工作。随着这一关键节点的达成，公司下一步将着手进行数据揭盲，以评估其候选药物的有效性与安全性。这一进展标志着该药物在神经修复领域的临床开发迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193065506","title":"NervGen Pharma宣布成功完成二期临床试验结束会议，并与FDA就慢性四肢瘫痪治疗药物Nvg-291的三期注册研究\"Restore\"达成共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1193065506","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193065506?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:31","pubTimestamp":1775561476,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp. 近日宣布，已成功完成针对其候选药物Nvg-291用于治疗慢性四肢瘫痪的三期注册研究\"Restore\"的二期临床试验结束会议。此次会议取得了积极成果，公司与美国食品药品监督管理局（FDA）就三期研究的整体开发计划达成了一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nervgen.com","stockEarnings":[{"period":"1week","weight":-0.4465},{"period":"1month","weight":-0.4623},{"period":"3month","weight":-0.5048},{"period":"6month","weight":-0.5164},{"period":"1year","weight":-0.4951},{"period":"ytd","weight":-0.6304}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NervGen Pharma Corp.于2017年1月19日根据商业公司法（不列颠哥伦比亚省）注册成立。该公司专注于为神经损伤和神经退行性疾病的治疗创造创新解决方案。该公司正在开发用于治疗脊髓损伤、多发性硬化症和阿尔茨海默病的药物。该公司只从事单一业务，即药物研发。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.065075},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.083353},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.174121},{"month":4,"riseRate":0.571429,"avgChangeRate":0.094833},{"month":5,"riseRate":0.375,"avgChangeRate":0.049851},{"month":6,"riseRate":0.285714,"avgChangeRate":0.000113},{"month":7,"riseRate":0.571429,"avgChangeRate":0.006979},{"month":8,"riseRate":0.714286,"avgChangeRate":0.041996},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.069975},{"month":10,"riseRate":0.571429,"avgChangeRate":0.07195},{"month":11,"riseRate":0.571429,"avgChangeRate":0.142341},{"month":12,"riseRate":0.714286,"avgChangeRate":0.21291}],"exchange":"NASDAQ","name":"NervGen Pharma Corp.","nameEN":"NervGen Pharma Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NervGen Pharma Corp.(NGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NervGen Pharma Corp.(NGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NervGen Pharma Corp.,NGEN,NervGen Pharma Corp.股票,NervGen Pharma Corp.股票老虎,NervGen Pharma Corp.股票老虎国际,NervGen Pharma Corp.行情,NervGen Pharma Corp.股票行情,NervGen Pharma Corp.股价,NervGen Pharma Corp.股市,NervGen Pharma Corp.股票价格,NervGen Pharma Corp.股票交易,NervGen Pharma Corp.股票购买,NervGen Pharma Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NervGen Pharma Corp.(NGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NervGen Pharma Corp.(NGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}